0001209191-17-059626.txt : 20171107 0001209191-17-059626.hdr.sgml : 20171107 20171107170649 ACCESSION NUMBER: 0001209191-17-059626 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171107 FILED AS OF DATE: 20171107 DATE AS OF CHANGE: 20171107 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GEMAYEL GEORGES CENTRAL INDEX KEY: 0001256088 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37601 FILM NUMBER: 171184288 MAIL ADDRESS: STREET 1: 550 HILLS DRIVE CITY: BEDMINSTER STATE: NJ ZIP: 07921 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dimension Therapeutics, Inc. CENTRAL INDEX KEY: 0001592288 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 463942159 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 840 MEMORIAL DRIVE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-401-0011 MAIL ADDRESS: STREET 1: 840 MEMORIAL DRIVE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-11-07 1 0001592288 Dimension Therapeutics, Inc. DMTX 0001256088 GEMAYEL GEORGES C/O DIMENSION THERAPEUTICS, INC. 840 MEMORIAL DRIVE, 4TH FLOOR CAMBRIDGE MA 02139 1 0 0 0 Stock Option (Right to Buy) 4.85 2017-11-07 4 D 0 44474 D 2025-08-11 Common Stock 44474 0 D Stock Option (Right to Buy) 7.08 2017-11-07 4 D 0 32069 D 2026-05-18 Common Stock 32069 0 D Stock Option (Right to Buy) 1.15 2017-11-07 4 D 0 17000 D 2027-05-24 Common Stock 17000 0 D This stock option, which vests in equal monthly installments over 48 months beginning July 15, 2015, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx. These options were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. These options, which vest in full on the earlier of May 25, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board, were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. /s/ Mary Thistle, as Attorney-in-Fact for Georges Gemayel 2017-11-07